Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Mai-Thao Nguyen

Family Medicine Yukon, OK Medical Doctor

NPI 1962815217 CMS profile 504797

11900 Nw Expressway, Yukon, OK 73099

Open in the dashboard

General payments

$2,422

176 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Mai-Thao Nguyen of Yukon, OK is reported in the CMS Open Payments database as having received $2,422 across 176 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $23 1
2021 General $238 16
2020 General $1,077 79
2019 General $1,084 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mai-Thao Nguyen
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Mai-Thao Nguyen were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Mai-Thao Nguyen Family Medicine median Middle half National median
2019 $1,084 $150 $41–$543 $163
2020 $1,077 $120 $32–$415 $114
2021 $238 $137 $35–$551 $132
2022 $23 $137 $37–$512 $149
2023 $0 $149 $42–$545 $160
2024 $0 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Pfizer Inc. $660 52 payments
  2. AstraZeneca Pharmaceuticals LP $243 13 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $239 16 payments
  4. Novo Nordisk Inc $218 19 payments
  5. Amgen Inc. $180 15 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $113 9 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $99 7 payments
  8. Merck Sharp & Dohme Corporation $97 7 payments
  9. Lilly USA, LLC $86 6 payments
  10. Janssen Pharmaceuticals, Inc $84 6 payments
  11. Other $402 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $2,412 175 payments
  2. Education $9 1 payment
Products named General payments · program years 2019–2022
  1. ELIQUIS $471 34 payments
  2. CHANTIX Neuroscience;Tobacco Dependence $238 20 payments
  3. CHANTIX Neuroscience;Tobacco Dependence $220 17 payments
  4. EUCRISA $209 20 payments
  5. COLOGUARD $209 20 payments
  6. Trintellix $196 13 payments
  7. Entyvio $196 13 payments
  8. Dexilant $196 13 payments
  9. Vyvanse $196 13 payments
  10. Motegrity $196 13 payments
  11. Other $2,517 179 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

176 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record